{"id":14686,"date":"2026-02-21T03:13:07","date_gmt":"2026-02-21T03:13:07","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/14686\/"},"modified":"2026-02-21T03:13:07","modified_gmt":"2026-02-21T03:13:07","slug":"novartis-to-exit-listed-indian-arm-in-rs-1446cr-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/14686\/","title":{"rendered":"Novartis to exit listed Indian arm in Rs 1,446cr deal"},"content":{"rendered":"<p> <img src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/novartis-india-stake-sale.jpg\" alt=\"Novartis to exit listed Indian arm in Rs 1,446cr deal\" title=\"Novartis\" decoding=\"async\" fetchpriority=\"high\"\/> New Delhi: Swiss drug firm Novartis will sell its entire stake of nearly 71% in its listed Indian subsidiary for about Rs 1,446 crore to a clutch of private equity investors, led by ChrysCapital. The exit comes two years after the parent began a strategic review of its Indian subsidiary, including assessing its stake in the Mumbai-based firm, with the objective to focus on high-value, innovation-led medicines.  Novartis said in a regulatory filing it has notified the Novartis India board that it has entered into an agreement with ChrysCapital, WaveRise Investments and Two Infinity Partners to transfer its 70.7% shareholding. The group also announced a mandatory open offer to buy an additional 26% of the company at Rs 861 per share. Novartis India closed 20% up at Rs 997 on BSE on Friday. At Davos 2025, Novartis global CEO Vas Narasimhan reaffirmed that the divestment remains on track while underscoring Novartis&#8217;s commitment to India&#8217;s long-term potential.  The firm operates in India through two entities: the listed company with its legacy portfolio, and the unlisted Novartis Healthcare with its high-value innovative medicines. After the deal, the parent will retain the latter, and expand its portfolio of cardio, renal, metabolic and oncology portfolio.<\/p>\n","protected":false},"excerpt":{"rendered":"New Delhi: Swiss drug firm Novartis will sell its entire stake of nearly 71% in its listed Indian&hellip;\n","protected":false},"author":2,"featured_media":14687,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[9992,10572,206,9922,10571,10086],"class_list":{"0":"post-14686","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-chryscapital","9":"tag-listed-indian-arm","10":"tag-novartis","11":"tag-novartis-india","12":"tag-private-equity-investors","13":"tag-strategic-review"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/14686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=14686"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/14686\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/14687"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=14686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=14686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=14686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}